Dyadic and medytox to develop vaccines against covid-19 variants

Jupiter, fla., march 23, 2021 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the company is expanding its partnership with south korea's medytox, inc. (“medytox”), a global biopharmaceutical company with sales in approximately 60 countries. dyadic and medytox will co-develop c1 manufactured covid-19 vaccines and/or boosters, which will, if successful, be used to immunize people against two or more of the current and future covid-19 variants. this project can provide dedicated local supply, to help combat covid-19, in this region of the world.
DYAI Ratings Summary
DYAI Quant Ranking